H.C. Wainwright lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $4 from $11 and keeps a Buy rating on the shares. The firm cites the company’s two “highly dilutive” financing transactions in June and September for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH: